• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

    28.25 UNCHANGED
    Streaming Delayed Price Updated: 4:15 PM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 253
    Open 28.25
    Bid (Size) 28.20 (100)
    Ask (Size) 28.85 (300)
    Prev. Close 28.25
    Today's Range 28.25 - 28.25
    52wk Range 12.91 - 42.13
    Shares Outstanding 60,717,176
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
    From Robbins Geller Rudman & Dowd LLP
    Via Business Wire
    News headline image
    Why Travere Therapeutics Stock Got Trounced on Tuesday ↗
    A regulatory decision on a top investigational drug won't be coming as soon as hoped. 
    Via The Motley Fool

    Performance

    YTD
    -28.5%
    -28.5%
    1 Month
    -22.6%
    -22.6%
    3 Month
    +2.8%
    +2.8%
    6 Month
    +75.1%
    +75.1%
    1 Year
    +45.2%
    +45.2%

    More News

    Read More
    News headline image
    Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
    Via MarketMinute
    Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗
    Via Stocktwits
    Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors ↗
    Via Chartmill
    News headline image
    Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗
    Via Stocktwits
    News headline image
    Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
    From Travere Therapeutics, Inc.
    Via Business Wire
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Tuesday. ↗
    Via Chartmill
    News headline image
    Travere Therapeutics Provides Corporate Update and 2026 Outlook
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗
    Via The Motley Fool
    News headline image
    Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗
    Via Chartmill
    News headline image
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
    Via Investor's Business Daily
    News headline image
    This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
    Via The Motley Fool
    News headline image
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Travere Therapeutics to Participate at Upcoming Investor Conferences
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat ↗
    Via Investor's Business Daily
    Topics Earnings
    News headline image
    Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments ↗
    Via Chartmill

    Frequently Asked Questions

    Is Travere Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
    Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
    The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
    What is the current price of Travere Therapeutics, Inc. - Common Stock?
    The current price of Travere Therapeutics, Inc. - Common Stock is 28.25
    When was Travere Therapeutics, Inc. - Common Stock last traded?
    The last trade of Travere Therapeutics, Inc. - Common Stock was at 01/21/26 04:15 PM ET
    What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
    The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.72B
    How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
    Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.